A randomized trial involving 77 participants with Parkinson's disease demonstrated that behavioral therapy is as effective as solifenacin, a common medication for overactive bladder (OAB). This 12-week study compared pelvic floor exercises and behavioral methods against the antimuscarinic drug. Both approaches significantly reduced urinary symptoms, with minimal side effects in the therapy group, indicating that behavioral therapy could be a viable first-line treatment. The research highlights the potential for high adherence and fewer drug-related complications among patients.

Source: JAMA Neurology